Swiss Medica Announces Strategic Alliance with MIT Scientists As Part of Recent Acquisition of Anti-Depression BioHealth Solutions Inc

Business Wire, April 6, 2005

TORONTO -- Swiss Medica (OTCBB:SWME) is pleased to announce its business relationship with two distinguished Massachusetts Institute of Technology (MIT) scientists through its recent acquisition of Anti-Depression BioHealth Solutions Inc. ("ADBS"). As part of the terms of the alliance, Swiss Medica has an option to acquire all over-the-counter products developed by Back Bay Scientific Inc. and this proven team of world class scientists, with certain limited exceptions.

Back Bay Scientific's products have been developed through the research conducted by Doctors Richard and Judith Wurtman. The married MIT scientists have a long history of groundbreaking research and successful products, including the patented discovery of new uses for Prozac. They have authored many publications in leading research journals, and Dr. Judith Wurtman has also appeared in the national mainstream media on numerous occasions, including the Oprah television show.

Richard Wurtman M.D. is the Cecil H. Green Distinguished Professor of Neuropharmacology and Director, Clinical Research Center, at the Massachusetts Institute of Technology (MIT) at the Department of Brain and Cognitive Sciences. Judith Wurtman, PhD is the author of five books, the most recent being The Serotonin Solution. She received her B.A. at Wellesley College, her M.A. at the Harvard Graduate School of Education, and her PhD. at George Washington University. She currently directs the program in Women's Health at the MIT Clinical Research Center, MIT, Cambridge and is the co-founder of ADARA a private weight loss practice in Boston. Dr. Wurtman's research has focused on the connection between the brain, behavior, and eating. Doctors Richard and Judith Wurtman identified the brain chemical serotonin as being involved in the abnormal food intake of obese carbohydrate cravers, women and premenstrual syndrome, smoking withdrawal, and Seasonal Affective Disorder.

"We are tremendously excited about this alliance because we believe Swiss Medica now has a product development arm that is second to none," explained Raghu Kilambi, CEO of Swiss Medica. "The products developed by Doctors Richard and Judith Wurtman will allow us to continue to build on the success of our flagship O24 product and help us to fulfill our mission to be a world leader in the commercialization of life enhancing bioscience products."

About Back Bay Scientific Inc.

Back Bay Scientific is a research-oriented company engaged in the development and commercialization of products that address popular, mass-appeal health issues, with a special emphasis on women's health and quality of life enhancement.

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com and www.O24zone.com

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals in the United States, Canada and in Europe. O24 is widely available throughout Canada in leading pharmacies and natural food stores. It is currently sold in an increasing number of pharmacies throughout the United States. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Swiss Medica Inc. (OTC Bulletin Board:SWME)